BRIEF-Novartis Says Health Canada Approved Kisqali As Initial Therapy For Certain Breast Cancer Patients

1 Min Read

May 2 (Reuters) - Novartis AG:

* HEALTH CANADA APPROVES KISQALI™ FOR THE TREATMENT OF HR-POSITIVE AND HER2-NEGATIVE METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN IN COMBINATION WITH LETROZOLE AS AN INITIAL ENDOCRINE-BASED THERAPY Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.

0 : 0

narrow-browser-and-phone
medium-browser-and-portrait-tablet
landscape-tablet
medium-wide-browser
wide-browser-and-larger
medium-browser-and-landscape-tablet
medium-wide-browser-and-larger
above-phone
portrait-tablet-and-above
above-portrait-tablet
landscape-tablet-and-above
landscape-tablet-and-medium-wide-browser
portrait-tablet-and-below
landscape-tablet-and-below